UNASSIGNED: Data on new cases of EOEC, EOGC and EOCRC were obtained from publicly available annual reports of the Iranian National Population-based Cancer Registry (INPCR). Incidence rates were calculated using the population data available from the Statistical center of Iran. We considered the World standard population for calculation of age-standardized incidence rates (ASR). We also calculated 95% confidence intervals (CIs) for ASR. All rates are presented per 100000 person-years.
UNASSIGNED: Overall, 19,679 new cases of EOGIC were registered by the INPCR between 2014 and 2018. The ASRs (95% CI) of EOEC, EOGC and EOCRC were 0.49 (95% CI: 0.47-0.51), 1.67 (1.63-1.71), and 3.07 (3.01-3.13) per 100,000 person-years, respectively. Our findings indicate decreasing and constant trends in the ASR of EOEC and EOGC during the study period, 2014-2018. There was an increasing trend in the ASR of EOCRC. We also found geographical disparities in the incidence rates of EOGICs across provinces of Iran, suggesting the highest ASRs of EOEC in Golestan (1.3), EOGC in Ilam (2.99) and EOCRC in Ilam (4.49).
UNASSIGNED: Our findings suggested that the incidence rate of EOCRC is consistently increasing. We also found variations in the incidence of EOGICs among different provinces. Further investigations are recommended to clarify the time trends and risk factors of EOGICs in Iran.
■关于EOEC新病例的数据,EOGC和EOCRC来自伊朗国家基于人群的癌症登记处(INPCR)的公开年度报告。发病率是使用伊朗统计中心提供的人口数据计算的。我们考虑了用于计算年龄标准化发病率(ASR)的世界标准人口。我们还计算了ASR的95%置信区间(CI)。所有费率均为每100000人年。
■总的来说,INPCR在2014年至2018年期间登记了19,679例新的EOGIC病例。EOEC的ASR(95%CI),EOGC和EOCRC为0.49(95%CI:0.47-0.51),1.67(1.63-1.71),和每100,000人年3.07(3.01-3.13),分别。我们的研究结果表明,在研究期间,EOEC和EOGC的ASR呈不断下降的趋势,2014-2018。EOCRC的ASR有增加的趋势。我们还发现,伊朗各省的EOGIC发病率存在地理差异,表明Golestan(1.3)中EOEC的最高ASR,伊拉姆的EOGC(2.99)和伊拉姆的EOCRC(4.49)。
■我们的研究结果表明,EOCRC的发病率持续增加。我们还发现不同省份之间的EOGIC发生率存在差异。建议进一步调查以澄清伊朗EOGIC的时间趋势和风险因素。